Cite
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
MLA
Benson Jr., Don M., et al. “A Phase 1 Trial of the Anti-KIR Antibody IPH2101 in Patients with Relapsed/Refractory Multiple Myeloma.” Blood, vol. 120, no. 21, Nov. 2012, pp. 4324–33. EBSCOhost, https://doi.org/10.1182/blood-2012-06-438028.
APA
Benson Jr., D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., Caligiuri, M. A., & Farag, S. S. (2012). A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood, 120(21), 4324–4333. https://doi.org/10.1182/blood-2012-06-438028
Chicago
Benson Jr., Don M., Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, et al. 2012. “A Phase 1 Trial of the Anti-KIR Antibody IPH2101 in Patients with Relapsed/Refractory Multiple Myeloma.” Blood 120 (21): 4324–33. doi:10.1182/blood-2012-06-438028.